ADMAADMA Biologics, Inc.
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internat…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 ADMA Q2 Earnings Meet, Revenues Miss on Bivigam Weakness ADMA Biologics matches earnings estimates, misses on revenues and maintains its 2026 outlook as strong Asceniv growth offsets continued pressure on Bivigam. | ||
ADMA Biologics Inc (ADMA) (Q2 2026) Earnings Call Highlights: Ascentiv Surges 24% as Gross ... ADMA Biologics Inc (ADMA) delivers strong Q2 2026 results with record Ascentiv growth and robust cash generation, despite persistent competitive pressures in the standard IG market. | ||
 ADMA Biologics Q2 Earnings Call Highlights ADMA Biologics (NASDAQ:ADMA) reported second-quarter revenue growth of 2% as increased sales of its ASCENIV immune globulin product offset pressure on BIVIGAM in the standard immunoglobulin market. The company reiterated its full-year financial outlook and said it remains on track to meet or exceed | ||
 Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note Adma Biologics (ADMA) closed the most recent trading day at $8.46, moving 2.42% from the previous trading session. | ||
 Wall Street Analysts See Adma Biologics (ADMA) as a Buy: Should You Invest? Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying? | ||
 Adma Biologics (ADMA) Rises Higher Than Market: Key Facts In the latest trading session, Adma Biologics (ADMA) closed at $8.48, marking a +2.54% move from the previous day. | ||
 Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note The latest trading day saw Adma Biologics (ADMA) settling at $8.59, representing a -1.83% change from its previous close. | ||
 ADMA Biologics (ADMA) Faces Class Actions And Probes Over Revenue Allegations Multiple securities class action lawsuits have been filed against ADMA Biologics (NasdaqGM:ADMA) following allegations of channel stuffing and misleading revenue recognition. Regulatory and internal investigations are underway into the company’s revenue practices, internal controls, and undisclosed related party transactions. The volume and scope of these legal actions introduce material questions around ADMA Biologics’ financial reporting and governance practices. ADMA Biologics operates... | ||
ADMA Biologics (ADMA) Stock Looks Undervalued Even After A 5 Year Run ADMA Biologics stock has delivered a very large 5 year return while its broader valuation checks still point to the shares looking inexpensive on several metrics, which puts the recent share price at US$8.87 under the spotlight. Over 5 years, ADMA Biologics has returned roughly 4.6x an initial investment, which puts current pricing in a very different context compared to where long term holders started. For the business to keep supporting this valuation, investors will be watching whether... | ||
 Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights Adma Biologics (ADMA) closed the most recent trading day at $8.97, moving 1.21% from the previous trading session. | ||
 Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views? The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock? | ||
IInsider Monkey | ||
IInsider Monkey | ||
IInsider Monkey | ||